Ortho Clinical Diagnostics Holdings plc (OCDX) Stock
OCDX is no longer traded. Ortho Clinical Diagnostics Holdings was acquired by QuidelOrtho (QDEL) on May 27, 2022.
Each OCDX share was exchanged for $7.14 in cash and 0.1 shares of Quidel common stock. Prices on this page are historical; the last trade was May 26, 2022 at $17.63.
See QuidelOrtho (QDEL) stock →Ortho Clinical Diagnostics Holdings stock price history
OCDX final trading statistics
- Final close
- $17.63
- Final trading day
- May 26, 2022
- Market cap at delisting
- $4.19B
- Shares outstanding
- 237.74M
- Final 52-week range
- $16.04 – $22.99
- Avg. volume (final 3 mo.)
- 1,151,607
- All-time high (split-adj.)
- $22.47 · Jul 2021
- All-time low (split-adj.)
- $15.88 · Mar 2021
- Return since IPO
- +9.5%
- Beta
- —
- Book value / share
- $1.86
- Price / book
- 9.45
Ortho Clinical Diagnostics Holdings annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $2.04B | -$54.3M | $0.81 |
| FY2020 | $1.77B | -$211.9M | $0.20 |
| FY2019 | $1.80B | -$156.9M | — |
| FY2018 | $1.79B | -$248.8M | — |
| FY2017 | $1.78B | -$116.3M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Ortho Clinical Diagnostics Holdings plc
Ortho Clinical Diagnostics Holdings plc provides in-vitro diagnostics solutions to the clinical laboratory and transfusion medicine communities worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company is also involved in the provision of contract manufacturing and orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. Ortho Clinical Diagnostics Holdings plc was founded in 1939 and is headquartered in Raritan, New Jersey. As of May 27, 2022, Ortho Clinical Diagnostics Holdings plc operates as a subsidiary of Quidel Corporation.
Ortho Clinical Diagnostics Holdings stock FAQ
What happened to Ortho Clinical Diagnostics Holdings stock?
Ortho Clinical Diagnostics Holdings was acquired by QuidelOrtho (QDEL) on May 27, 2022. Shareholders received $7.14 in cash and 0.1 shares of Quidel common stock for each share. OCDX stock stopped trading on the Nasdaq, with a final close of $17.63 on May 26, 2022.
What did Ortho Clinical Diagnostics Holdings shareholders receive?
Each OCDX share was converted into $7.14 in cash and 0.1 shares of Quidel common stock. The deal was valued at about $6 billion.
Is OCDX stock still trading?
No. OCDX was delisted from the Nasdaq on May 27, 2022 and no longer trades on a U.S. exchange. Former Ortho Clinical Diagnostics Holdings shareholders received QuidelOrtho (QDEL) shares.
What was the last price of OCDX stock?
OCDX closed at $17.63 on its final trading day, May 26, 2022, for a market value of about $4.19B.
What were Ortho Clinical Diagnostics Holdings's revenue and earnings in its last full fiscal year?
Ortho Clinical Diagnostics Holdings reported revenue of $2.04B and net income of -$54.3M in fiscal 2021, its last full year as a public company.
When did Ortho Clinical Diagnostics Holdings go public?
Ortho Clinical Diagnostics Holdings plc stock began trading on January 28, 2021.